Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUCET vs BUTABARB
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bucet is a combination of bucetin and acetaminophen. Bucetin is a para-aminophenol derivative with analgesic and antipyretic effects, possibly through inhibition of cyclooxygenase in the central nervous system. Acetaminophen inhibits COX enzymes in the brain, reducing prostaglandin synthesis and fever.
Barbiturate that binds to GABA-A receptor subunits, potentiating GABAergic inhibition by increasing chloride ion conductance and reducing neuronal excitability.
Management of mild to moderate pain,Reduction of fever
Sedative,Hypnotic,Anticonvulsant,Preoperative anxiety
Oral: 25-50 mg every 4-6 hours as needed for pain; maximum 200 mg/day.
15-30 mg orally 3-4 times daily as needed; maximum 200 mg/day. IV/IM: 50-200 mg for sedation.
2-4 hours (terminal); prolonged in renal impairment
Terminal elimination half-life is 30-60 hours (mean ~40 hours) in adults with normal renal and hepatic function. Longer in elderly or patients with liver disease.
Bucetin: Hepatic metabolism via hydroxylation and glucuronidation. Acetaminophen: Hepatic metabolism via glucuronidation, sulfation, and CYP2E1-mediated oxidation to NAPQI.
Hepatic metabolism via CYP2C9 and CYP2C19; minor pathways involve glucuronidation.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Renal excretion of unchanged drug and metabolites. Approximately 70-80% of a dose is eliminated in urine as metabolites (hydroxy and glucuronide conjugates) and <5% as parent drug. Minimal biliary/fecal elimination (<5%).
~85% bound to albumin
Approximately 20-25% bound to plasma proteins (albumin).
0.3-0.5 L/kg; distributes primarily into extracellular fluid
0.5-0.6 L/kg in adults. Higher Vd suggests distribution into total body water and tissues; may increase in obesity.
Oral: 75-90%
Oral: 95-100% (well absorbed). Rectal: 80-90%. IM: 80-100%.
GFR 10-50 m L/min: 50% dose reduction; GFR <10 m L/min: avoid use.
e GFR 30-50 m L/min: reduce dose by 25%. e GFR <30 m L/min: avoid use or use 50% reduction with caution.
Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
Children 6-12 years: 5 mg/kg/dose every 6 hours as needed; maximum 20 mg/kg/day.
0.5-1 mg/kg/dose orally every 6-8 hours; maximum 30 mg/dose. Not recommended for children under 6 years.
Start at lowest effective dose (12.5 mg every 6 hours); maximum 150 mg/day due to increased fall risk and renal impairment.
Initiate at 7.5-15 mg orally 2-3 times daily; increase slowly. Avoid in frail elderly. Monitor for paradoxical excitation.
No FDA black box warnings for bucet. Acetaminophen component: Risk of severe liver injury at high doses or with alcohol use.
May be habit forming; potential for abuse and dependence. Abrupt discontinuation may precipitate life-threatening withdrawal symptoms.
Hepatotoxicity risk with acetaminophen overdose,Avoid alcohol use,Hypersensitivity reactions,Skin reactions (Stevens-Johnson syndrome)
Respiratory depression, especially when combined with other CNS depressants; tolerance and dependence; withdrawal seizures; use with caution in hepatic impairment and elderly.
Severe hepatic impairment,Hypersensitivity to bucetin or acetaminophen
Hypersensitivity to barbiturates, porphyria, severe respiratory insufficiency, history of substance abuse.
No known food interactions. Avoid alcohol as it may increase risk of side effects like dizziness.
Avoid grapefruit juice as it may inhibit metabolism and increase sedative effects. Take with food if gastrointestinal upset occurs. Limit caffeine intake as it may reduce sedative efficacy.
FDA Pregnancy Category D. First trimester: Increased risk of cardiac malformations and neural tube defects. Second and third trimesters: Risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment.
Butabarbital is a barbiturate classified as FDA Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly oral clefts, neural tube defects, and cardiovascular anomalies. Second and third trimesters: Potential for fetal dependence, withdrawal syndrome, and impaired brain development. Chronic use may cause fetal growth restriction and preterm birth.
Contraindicated. Excreted in human milk; M/P ratio not established. Potential for serious adverse effects in nursing infant.
Barbiturates are excreted into breast milk in low concentrations. M/P ratio is approximately 0.5-0.6. Chronic high-dose use may lead to infant sedation and difficulty feeding. Monitor infant for signs of drowsiness, lethargy, or poor suckling. Use caution, especially in neonates or preterm infants.
Avoid use during pregnancy. If unavoidable, reduce dose by 50% due to increased clearance and altered protein binding.
Pregnancy induces hepatic microsomal enzymes, increasing barbiturate metabolism. Higher doses (increased by 30-50%) may be required to maintain therapeutic levels. Monitor serum drug levels if needed, especially in third trimester. Postpartum, reduce dose to prepregnancy levels to avoid toxicity.
Bucet (bupivacaine hydrochloride and epinephrine) is used for local anesthesia. Epinephrine prolongs anesthetic effect and reduces systemic absorption. Avoid in patients with severe hypertension, hyperthyroidism, or concurrent MAO inhibitors. Monitor for CNS and cardiac toxicity, especially with high doses. Epinephrine concentration is 1:200,000; check for allergy to sulfites (antioxidant).
Butabarbital is a short-acting barbiturate with a rapid onset; monitor for respiratory depression, especially when combined with other CNS depressants. Use with caution in hepatic impairment due to prolonged half-life. Tolerance and dependence develop with prolonged use; abrupt discontinuation may precipitate withdrawal seizures. Barbiturates induce CYP450 enzymes, potentially reducing efficacy of oral contraceptives, warfarin, and corticosteroids.
Do not drive or operate machinery until numbness subsides.,Avoid touching or scratching the numb area to prevent injury.,Report any signs of allergic reaction (rash, swelling, difficulty breathing) or intravenous injection symptoms (rapid heart rate, anxiety, headache).,The numbness will wear off over several hours depending on the dose and site.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they may cause severe sedation or respiratory depression.,Do not drive or operate heavy machinery until you know how this medication affects you.,Do not stop taking abruptly; withdrawal can cause anxiety, tremors, and seizures. Taper under medical supervision.,This medication may be habit-forming; store in a safe place to prevent misuse.,Notify your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Inform your doctor of all medications you take, including herbal supplements and over-the-counter drugs.
No interactions on record
"Butabarbital, a barbiturate, induces cytochrome P450 (CYP) enzymes, enhancing the hepatic metabolism of ketamine, a dissociative anesthetic primarily metabolized by CYP3A4 and CYP2B6. This interaction reduces ketamine's systemic exposure and anesthetic efficacy, potentially leading to suboptimal sedation or anesthesia. Additionally, concurrent use may increase the risk of respiratory depression and hypotension due to additive central nervous system (CNS) depressant effects."
"Butabarbital, a barbiturate, is a potent CNS depressant that acts primarily by potentiating GABA-A receptor activity. Metaxalone is a centrally acting muscle relaxant with sedative properties. Coadministration results in additive or synergistic CNS depression, leading to increased risk of excessive sedation, respiratory depression, impaired psychomotor function, and potential coma or death, especially at higher doses or in vulnerable patients."
"Butabarbital, a barbiturate sedative-hypnotic, induces hepatic cytochrome P450 enzymes, particularly CYP3A4, which are responsible for metabolizing the atypical antipsychotic paliperidone. This induction decreases plasma concentrations of paliperidone, potentially reducing its therapeutic efficacy in treating schizophrenia or bipolar disorder. Concomitant use may lead to relapse of psychiatric symptoms or necessitate dose adjustments."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUCET vs BUTABARB, answered by our medical review team.
BUCET is a Barbiturate Combination Analgesic that works by Bucet is a combination of bucetin and acetaminophen. Bucetin is a para-aminophenol derivative with analgesic and antipyretic effects, possibly through inhibition of cyclooxygenase in the central nervous system. Acetaminophen inhibits COX enzymes in the brain, reducing prostaglandin synthesis and fever.. BUTABARB is a Barbiturate that works by Barbiturate that binds to GABA-A receptor subunits, potentiating GABAergic inhibition by increasing chloride ion conductance and reducing neuronal excitability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUCET and BUTABARB depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUCET is: Oral: 25-50 mg every 4-6 hours as needed for pain; maximum 200 mg/day.. The standard adult dose of BUTABARB is: 15-30 mg orally 3-4 times daily as needed; maximum 200 mg/day. IV/IM: 50-200 mg for sedation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUCET and BUTABARB in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUCET is classified as Category C. FDA Pregnancy Category D. First trimester: Increased risk of cardiac malformations and neural tube defects. Second and third trimesters: Risk of premature closure of ductus arterio. BUTABARB is classified as Category C. Butabarbital is a barbiturate classified as FDA Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly oral clefts, neural tube defects, an. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.